Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis
Sponsor:The Cleveland ClinicBrief Summary: The need for improved diagnostic methods in Multiple Sclerosis (MS) is widely recognized. Although Magnetic Resonance…
[searchandfilter fields="search,category" post_types="post"]
Long-term, Prospective,Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy
Sponsor:Novartis PharmaceuticalsBrief Summary: The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly…
A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.
Sponsor:University of California, Los AngelesBrief Summary: Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition.…
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Sponsor:Novartis PharmaceuticalsBrief Summary: To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple…
A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
Sponsor:Sanguine BiosciencesBrief Summary: We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a…
A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis
Sponsor:Immune Response BioPharma, Inc.Brief Summary: Multi-center, randomized , double-blind, placebo-controlled , two arm parallel design study of NeuroVax™ vs. Incomplete…
A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination
Sponsor:Immune Response BioPharma, Inc.Brief Summary: Multi-center, randomized , double-blind, placebo-controlled , two arm parallel design study of NeuroVax™ vs. Incomplete…
